Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer
The Parker Institute for Cancer Immunotherapy and Cancer Research Institute in the US have started dosing patients in a Phase Ib/II clinical trial to investigate the combination of standard chemotherapy and immunotherapy for the treatment of pancreat …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Immunotherapy | Pancreas | Pancreatic Cancer | Pharmaceuticals